Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Pancreatic Ductal Adenocarcinoma × canakinumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Leukemia, Myelomonocytic, Chronic 1 Gastrointestinal Neoplasms 1 Clonal Cytopenia of Undetermined Significance 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 3 130-nm albumin-bound paclitaxel 3 spartalizumab 1 canakinumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04581343 2025-05-04

PanCAN-SR1

Pancreatic Cancer Action Network

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡